Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology In 21st Century Cures: Heading Toward A Two-FDA Solution?

Executive Summary

The 21st Century Cures Act regulatory reform provisions amount to a lot of little things: tweaks to encourage ongoing activities rather than bold departures at a time when the overall regulatory climate is good for innovators. But the law could also be the start of something bigger – a more formal division within the US FDA between oncology and everything else.

You may also be interested in...



US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say

CDER's OHOP, as well as relevant CBER and CDRH staff, should be folded into OCE, which should have final sign-off on all oncology products, ASCO and Friends of Cancer Research say.

US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb

Analyst poll of 53 drug companies indicates broad support for Scott Gottlieb compared to three other known candidates for FDA Commissioner.

CDER’s 50 Open Leadership Posts Could Be Bigger Hiring Challenges After Trump Freeze

President Trump’s hiring freeze on civilian employees will exacerbate the Center for Drugs Evaluation & Research’s existing difficulties in recruiting and retaining qualified individuals. CDER is currently 591 positions under the hiring ceiling, include 50 open positions within CDER management.

Related Content

Topics

UsernamePublicRestriction

Register

PS119801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel